# Xdemvy (lotilaner) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lotilaner

> The FDA approved Xdemvy (lotilaner), sponsored by Tarsus Pharmaceuticals, Inc. (TARS), on July 24, 2023 for to treat Demodex blepharitis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Xdemvy (lotilaner) |
| Codes |  |
| Sponsor | Tarsus Pharmaceuticals, Inc. (TARS) https://sec-api.dev/companies/tars/catalysts |
| Indications | To treat Demodex blepharitis, [Ocular Rosacea](https://sec-api.dev/indications/ocular-rosacea) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 24, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat Demodex blepharitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Xdemvy | lotilaner | 7/25/2023 | To treat Demodex blepharitisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA217603 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230724, review_priority STANDARD; sponsor_name TARSUS; product XDEMVY (LOTILANER)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217603%22

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ocular Rosacea.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07443202

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ocular Rosacea.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07443202

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lotilaner.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Xdemvy (lotilaner) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lotilaner

```bibtex
@misc{secapidev_pdufa_lotilaner_20261116,
  title        = {Xdemvy (lotilaner) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lotilaner}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lotilaner_20261116","title":"Xdemvy (lotilaner) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lotilaner","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
